Abstract:Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually diagnosed in advanced stages due to late symptom manifestation with very limited therapeutic options, which leads to ineffective intervention and dismal prognosis. For a decade, tyrosine kinase inhibitors (TKIs) have offered an overall survival (OS) benefit when used in a first-line (sorafenib and lenvatinib) and second-line setting (regorafenib and cabozantinib) in advanced HCC, while long-term response remains unsatisfactory due to the onset of primary or acquired resistance. Recently, immunotherapy has emerged as a promising therapy in the treatment of several solid tumors, such as melanoma and non-small cell lung cancer. Moreover, as the occurrence of HCC is associated with immune tolerance and immunosurveillance escape, there is a potent rationale for employing immunotherapy in HCC. However, immunotherapy monotherapy, mainly including immune checkpoint inhibitors (ICIs) that target checkpoints programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and the cytotoxic T lymphocyte antigen-4 (CTLA-4), has a relatively low response rate. Thus, the multi-ICIs or the combination of immunotherapy with other therapies, like antiangiogenic drugs and locoregional therapies, has become a novel strategy to treat HCC. Combining different ICIs may have a synergistical effect attributed to the complementary effects of the two immune checkpoint pathways (CTLA-4 and PD-1/PD-L1 pathways). The incorporation of antiangiogenic drugs in ICIs can enhance antitumor immune responses via synergistically regulating the vasculature and the immune microenvironment of tumor. In addition, locoregional treatments can improve antitumor immunity by releasing the neoplasm antigens from killed tumor cells; in turn, this antitumor immune response can be intensified by immunotherapy. Therefore, the combination of locoregional treatments and immunotherapy may achieve greater efficacy through further synergistic effects for advanced HCC. This review aims to summarize the currently reported results and ongoing trials of the ICIs-based combination therapies for HCC to explore the rational combination strategies and further improve the survival of patients with HCC.

Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma

New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Locoregional Combined with Systemic Therapies for Advanced Hepatocellular Carcinoma: an Inevitable Trend of Rapid Development

Combined Immunotherapy for Hepatocellular Carcinoma: How to Maximize Immune Checkpoint Blockade Synergic Anti-tumor Effect

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials

Locoregional therapies combined with immune checkpoint inhibitors for liver metastases

Combination of Molecularly Targeted Therapies and Immune Checkpoint Inhibitors in the New Era of Unresectable Hepatocellular Carcinoma Treatment

Radiation therapy in the era of immune treatment for hepatocellular carcinoma

Strategies for Improving the Efficacy of Immunotherapy in Hepatocellular Carcinoma

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives

The current status and future of targeted-immune combination for hepatocellular carcinoma

Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma

Combining Radiation with Immune Checkpoint Inhibitors Therapy for HCC: from the Alteration of the Immune Microenvironment by Radiotherapy

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

Immune Checkpoint Inhibitors in the Treatment of HCC